CN108348534A - 治疗与cns水肿相关的损伤或状况的方法 - Google Patents

治疗与cns水肿相关的损伤或状况的方法 Download PDF

Info

Publication number
CN108348534A
CN108348534A CN201680066630.6A CN201680066630A CN108348534A CN 108348534 A CN108348534 A CN 108348534A CN 201680066630 A CN201680066630 A CN 201680066630A CN 108348534 A CN108348534 A CN 108348534A
Authority
CN
China
Prior art keywords
subject
sur1
hours
administering
injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680066630.6A
Other languages
English (en)
Chinese (zh)
Inventor
S.M.雅各布森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Chesapeake LLC
Original Assignee
Biogen Chesapeake LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Chesapeake LLC filed Critical Biogen Chesapeake LLC
Priority to CN202211412393.8A priority Critical patent/CN115737816A/zh
Publication of CN108348534A publication Critical patent/CN108348534A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201680066630.6A 2015-10-07 2016-10-07 治疗与cns水肿相关的损伤或状况的方法 Pending CN108348534A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211412393.8A CN115737816A (zh) 2015-10-07 2016-10-07 治疗与cns水肿相关的损伤或状况的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562238461P 2015-10-07 2015-10-07
US62/238,461 2015-10-07
PCT/US2016/055988 WO2017062765A1 (en) 2015-10-07 2016-10-07 Methods of treating injuries or conditions related to cns edema

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211412393.8A Division CN115737816A (zh) 2015-10-07 2016-10-07 治疗与cns水肿相关的损伤或状况的方法

Publications (1)

Publication Number Publication Date
CN108348534A true CN108348534A (zh) 2018-07-31

Family

ID=58488580

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680066630.6A Pending CN108348534A (zh) 2015-10-07 2016-10-07 治疗与cns水肿相关的损伤或状况的方法
CN202211412393.8A Pending CN115737816A (zh) 2015-10-07 2016-10-07 治疗与cns水肿相关的损伤或状况的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211412393.8A Pending CN115737816A (zh) 2015-10-07 2016-10-07 治疗与cns水肿相关的损伤或状况的方法

Country Status (15)

Country Link
US (4) US20180280325A1 (cg-RX-API-DMAC7.html)
EP (1) EP3359162B1 (cg-RX-API-DMAC7.html)
JP (5) JP7349786B2 (cg-RX-API-DMAC7.html)
KR (3) KR20240105519A (cg-RX-API-DMAC7.html)
CN (2) CN108348534A (cg-RX-API-DMAC7.html)
AU (3) AU2016335767B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018006925A2 (cg-RX-API-DMAC7.html)
CA (1) CA3001321A1 (cg-RX-API-DMAC7.html)
EA (1) EA201890893A1 (cg-RX-API-DMAC7.html)
ES (1) ES2940669T3 (cg-RX-API-DMAC7.html)
HK (1) HK1257542A1 (cg-RX-API-DMAC7.html)
IL (1) IL258509B2 (cg-RX-API-DMAC7.html)
MA (1) MA45574A (cg-RX-API-DMAC7.html)
MX (1) MX392466B (cg-RX-API-DMAC7.html)
WO (1) WO2017062765A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115836050A (zh) * 2020-07-17 2023-03-21 上海森辉医药有限公司 磺酰脲类衍生物及其医药用途
CN120827620A (zh) * 2024-04-22 2025-10-24 瑞迪制药有限公司 治疗有大脑水肿或小脑水肿风险的缺血性卒中的方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104602682B (zh) 2012-05-08 2018-12-14 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
EP3065729A4 (en) 2013-11-06 2017-05-31 Aeromics, Inc. Novel formulations
KR20240105519A (ko) * 2015-10-07 2024-07-05 레메디 파마슈티칼즈, 인크. Cns 부종과 관련한 손상 또는 병태의 치료 방법
WO2020041905A1 (en) * 2018-08-31 2020-03-05 The University Of British Columbia Methods for identifying compounds suitable for treatment of central nervous system trauma and uses of those compounds
JP2022531312A (ja) * 2019-05-02 2022-07-06 バイオジェン チェサピーク エルエルシー 中枢神経系挫傷に苦しむ対象の治療方法
WO2025212154A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
WO2025212189A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema using a sur1-trpm4 channel inhibitor
WO2025212155A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke with large vessel occlusion using a sur1-trpm4 channel inhibitor
US12251388B1 (en) * 2024-05-09 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276411A1 (en) * 2002-03-20 2006-12-07 University Of Maryland, Baltimore Novel non-selective cation channel in neuronal cells and methods for treating brain swelling
US20130203853A1 (en) * 2010-07-19 2013-08-08 Remedy Pharmaceuticals, Inc. Methods of intravenous administration of glyburide and other drugs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856360A (en) 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
ES2807274T3 (es) * 2002-03-20 2021-02-22 Univ Maryland Un canal catiónico no selectivo en células neurales y compuestos que bloquean el canal para su uso en el tratamiento de la inflamación del cerebro
US20050246000A1 (en) * 2004-05-03 2005-11-03 Seacoast Technologies, Inc. Cooled craniectomy
CA2691199C (en) 2007-06-22 2017-09-12 Marc J. Simard Inhibitors of ncca-atp channels for therapy
CA3123813C (en) * 2007-12-04 2024-10-08 Remedy Pharmaceuticals, Inc. IMPROVED GLIBENCLAMIDE FORMULATIONS AND RELATED FREEZE-DRYING METHODS, AND FREEZE-DRY SATE PRODUCED THUS
KR20240105519A (ko) 2015-10-07 2024-07-05 레메디 파마슈티칼즈, 인크. Cns 부종과 관련한 손상 또는 병태의 치료 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276411A1 (en) * 2002-03-20 2006-12-07 University Of Maryland, Baltimore Novel non-selective cation channel in neuronal cells and methods for treating brain swelling
US20130203853A1 (en) * 2010-07-19 2013-08-08 Remedy Pharmaceuticals, Inc. Methods of intravenous administration of glyburide and other drugs

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115836050A (zh) * 2020-07-17 2023-03-21 上海森辉医药有限公司 磺酰脲类衍生物及其医药用途
CN115836050B (zh) * 2020-07-17 2024-12-20 上海森辉医药有限公司 磺酰脲类衍生物及其医药用途
CN120827620A (zh) * 2024-04-22 2025-10-24 瑞迪制药有限公司 治疗有大脑水肿或小脑水肿风险的缺血性卒中的方法

Also Published As

Publication number Publication date
BR112018006925A2 (pt) 2018-10-16
IL258509B2 (en) 2023-04-01
US20180280325A1 (en) 2018-10-04
KR20240105519A (ko) 2024-07-05
AU2025202620A1 (en) 2025-05-01
US20250017880A1 (en) 2025-01-16
JP7592768B2 (ja) 2024-12-02
JP7810762B2 (ja) 2026-02-03
ES2940669T3 (es) 2023-05-10
HK1257542A1 (zh) 2019-10-25
CA3001321A1 (en) 2017-04-13
JP2026069546A (ja) 2026-04-23
US11951085B2 (en) 2024-04-09
MA45574A (fr) 2019-05-15
MX392466B (es) 2025-03-24
KR20180063296A (ko) 2018-06-11
AU2016335767A8 (en) 2018-06-28
EP3359162A4 (en) 2019-08-28
KR102681027B1 (ko) 2024-07-02
JP2018530564A (ja) 2018-10-18
AU2022279369B2 (en) 2025-02-13
US20240216309A1 (en) 2024-07-04
IL258509B (en) 2022-12-01
JP2021073317A (ja) 2021-05-13
CN115737816A (zh) 2023-03-07
US20220125750A1 (en) 2022-04-28
EP3359162B1 (en) 2022-12-21
AU2022279369A1 (en) 2023-01-19
JP2024164167A (ja) 2024-11-26
AU2016335767B2 (en) 2022-10-06
KR20260093449A (ko) 2026-06-19
JP7349786B2 (ja) 2023-09-25
JP2023053274A (ja) 2023-04-12
WO2017062765A1 (en) 2017-04-13
EA201890893A1 (ru) 2018-09-28
EP3359162A1 (en) 2018-08-15
MX2018004286A (es) 2018-08-09
AU2016335767A1 (en) 2018-05-24
IL258509A (en) 2018-05-31

Similar Documents

Publication Publication Date Title
US11951085B2 (en) Methods of treating injuries or conditions related to CNS edema
US20250161330A1 (en) Methods of medical treatment with sur1-trpm4 channel inhibitors
JP2018530564A5 (cg-RX-API-DMAC7.html)
EP4096703A1 (en) Therapeutic uses of tirzepatide
Ibrahim et al. A Comparative Study of Infusion of Ephedrine and Phenylephrine on Hemodynamic Stability After Spinal Anesthesia in Elderly Patients Undergoing Lower Limb Orthopedic Surgeries.
JP2022531312A (ja) 中枢神経系挫傷に苦しむ対象の治療方法
US20260115210A1 (en) Method for treating subjects suffering from central nervous system contusions
JP2019515012A (ja) スタンソポルフィン及び光線療法を用いて高ビリルビン血症を治療するための方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1257542

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180731

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1257542

Country of ref document: HK